Amylyx Pharmaceuticals, Inc. (AMLX) FY2025 10-K Annual Report
Amylyx Pharmaceuticals, Inc. (AMLX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Amylyx Pharmaceuticals, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage pharma developing novel therapies for endocrine and neurodegenerative diseases with mechanistic rationale and biomarker-driven pipeline
- • New products: Advanced Phase 3 trial for avexitide in PBH; initiated Phase 1 trial for AMX0114 in ALS and selected AMX0318 for long-acting GLP-1 antagonist development
- • Strategic shift: Acquired avexitide patent portfolio in July 2024, expanding IP estate significantly; emphasis on broader rare disease indications including Wolfram syndrome and ALS
- • Quantitative metric: Patent estate grew to 23 U.S. and 257 foreign issued patents plus 130+ pending applications as of Dec 31, 2025; 75 participants enrolled in Phase 3 LUCIDITY trial
- • Noteworthy fact: Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome showing sustained pancreatic beta cell function improvement through 48 weeks
Management Discussion & Analysis
- • Revenue $0 in 2025 vs $87.4M in 2024, 100% decline due to discontinuation of RELYVRIO®/ALBRIOZA™ product sales
- • Operating loss $153.3M in 2025 vs $314.7M in 2024, a 51% improvement; R&D expenses down 13% to $90.4M; SG&A down 45% to $62.9M
- • Best performing segment: Avexitide R&D up 771% to $24.1M; worst: AMX0035-ALS R&D down 95% to $1.8M
- • Cash from financing $257.0M in 2025 led by two equity offerings raising approx. $256.2M net; operating cash burn $123.3M; cash & equivalents $317.0M at year-end
- • Management expects R&D and G&A expenses to increase as clinical programs advance; key risks include clinical trial outcomes, regulatory approvals, and capital access
Risk Factors
- • Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
- • Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy
- • Reliance on external vendors for managed network support and security operations creating supply chain cybersecurity risk
Amylyx Pharmaceuticals, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$0
▼ -100.0% YoY
Net Income
-$145M
▲ +52.0% YoY
ROE
-47.4%
▲ +13572bp YoY
Total Assets
$333M
▲ +71.8% YoY
EPS (Diluted)
$-1.53
▲ +65.5% YoY
Operating Cash Flow
-$123M
▲ +26.4% YoY
Source: XBRL data from Amylyx Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amylyx Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.